KURA
Price
$9.01
Change
-$0.30 (-3.22%)
Updated
Jul 31 closing price
Capitalization
799.86M
Earnings call today
Intraday BUY SELL Signals
ZBIO
Price
$31.44
Change
-$0.83 (-2.57%)
Updated
Jul 31 closing price
Capitalization
1.98B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs ZBIO

KURA vs ZBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KURA vs. ZBIO commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and ZBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (KURA: $9.01 vs. ZBIO: $31.44)
Brand notoriety: KURA and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 52% vs. ZBIO: 38%
Market capitalization -- KURA: $799.86M vs. ZBIO: $1.98B
KURA [@Biotechnology] is valued at $799.86M. ZBIO’s [@Biotechnology] market capitalization is $1.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 0 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • KURA’s FA Score: 0 green, 5 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both KURA and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 5 TA indicator(s) are bullish while ZBIO’s TA Score has 3 bullish TA indicator(s).

  • KURA’s TA Score: 5 bullish, 5 bearish.
  • ZBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, KURA is a better buy in the short-term than ZBIO.

Price Growth

KURA (@Biotechnology) experienced а -13.28% price change this week, while ZBIO (@Biotechnology) price change was +3.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

KURA is expected to report earnings on Aug 03, 2026.

ZBIO is expected to report earnings on Aug 18, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($1.99B) has a higher market cap than KURA($800M). KURA (-13.282) and ZBIO (-13.412) have similar YTD gains . KURA has higher annual earnings (EBITDA): -291.88M vs. ZBIO (-411.03M). ZBIO has more cash in the bank: 717M vs. KURA (581M). KURA has less debt than ZBIO: KURA (24.3M) vs ZBIO (267M). KURA has higher revenues than ZBIO: KURA (71.6M) vs ZBIO (0).
KURAZBIOKURA / ZBIO
Capitalization800M1.99B40%
EBITDA-291.88M-411.03M71%
Gain YTD-13.282-13.41299%
P/E RatioN/A1.63-
Revenue71.6M0-
Total Cash581M717M81%
Total Debt24.3M267M9%
FUNDAMENTALS RATINGS
KURA vs ZBIO: Fundamental Ratings
KURA
ZBIO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5235
P/E GROWTH RATING
1..100
10087
SEASONALITY SCORE
1..100
9070

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (49) in the Biotechnology industry is in the same range as ZBIO (54) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's SMR Rating (99) in the Biotechnology industry is in the same range as ZBIO (99) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (35) in the null industry is in the same range as KURA (52) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.

ZBIO's P/E Growth Rating (87) in the null industry is in the same range as KURA (100) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURAZBIO
RSI
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
71%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
79%
Bullish Trend 14 days ago
88%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KURA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DECZ43.200.32
+0.76%
TrueShares Structured Outcome Dec ETF
TDV98.990.74
+0.75%
ProShares S&PTech Div Arstcrts ETF
QQQX29.510.15
+0.51%
Nuveen NASDAQ 100 Dynamic Overwrite Fund
QIG43.47-0.03
-0.08%
WisdomTree US Corporate Bond
APLX9.75-0.45
-4.41%
Tradr 2X Long APLD Daily ETF

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with REPL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
-2.57%
REPL - ZBIO
41%
Loosely correlated
+107.02%
RZLT - ZBIO
37%
Loosely correlated
-3.28%
KURA - ZBIO
37%
Loosely correlated
-3.22%
NTLA - ZBIO
36%
Loosely correlated
-3.70%
AMLX - ZBIO
36%
Loosely correlated
-2.12%
More